2024
Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications
Gerke M, Jansen C, Bilen M. Circulating Tumor DNA in Genitourinary Cancers: Detection, Prognostics, and Therapeutic Implications. Cancers 2024, 16: 2280. PMID: 38927984, PMCID: PMC11201475, DOI: 10.3390/cancers16122280.Peer-Reviewed Original ResearchRenal cell carcinomaGU cancersProstate cancerBladder cancerGenitourinary (GU) cancersUtilization of liquid biopsyCastration-resistant prostate cancerDetect residual diseaseCirculating tumor DNATherapeutic response predictionCtDNA assaysResidual diseaseCtDNA analysisCell carcinomaTumor DNAGenitourinary cancersPrognostic informationClinical detection methodsTreatment responseGenomic alterationsLiquid biopsyClinical trialsTherapeutic implicationsCancerCtDNAUnderstanding and overcoming resistance to immunotherapy in genitourinary cancers
Evans S, Jani Y, Jansen C, Yildirim A, Kalemoglu E, Bilen M. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biology & Therapy 2024, 25: 2342599. PMID: 38629578, PMCID: PMC11028033, DOI: 10.1080/15384047.2024.2342599.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsResistance to immunotherapyImmunotherapy resistanceTargeted therapyGenitourinary (GU) cancersCombined immune checkpoint inhibitorsIntroduction of novel immunotherapiesMechanisms of immunotherapy resistanceOvercome resistance to immunotherapyCancer cellsHost immune profileResponse to immunotherapyNovel Targeted TherapiesImmune system's rolePredictors of responseAttack cancer cellsImmune system's abilityStandard of careCheckpoint inhibitorsSequential therapyNovel immunotherapiesCombination therapyTreatment failureGU cancersTreatment landscape
2021
Major Urological Cancer Surgery for Patients is Safe and Surgical Training Should Be Encouraged During the COVID-19 Pandemic: A Multicentre Analysis of 30-day Outcomes
Tan W, Arianayagam R, Khetrapal P, Rowe E, Kearley S, Mahrous A, Pal R, Fowler W, Heer R, Elajnaf M, Douglas-Moore J, Griffiths T, Voss J, Wilby D, Al Kadhi O, Noel J, Vasdev N, McKay A, Ahmad I, Abu-Nayla I, Lamb B, Hill G, Narahari K, Kynaston H, Yousuf A, Kusuma V, Cresswell J, Cooke P, Chakravarti A, Barod R, Bex A, Kelly J, group O. Major Urological Cancer Surgery for Patients is Safe and Surgical Training Should Be Encouraged During the COVID-19 Pandemic: A Multicentre Analysis of 30-day Outcomes. European Urology Open Science 2021, 25: 39-43. PMID: 33458711, PMCID: PMC7796655, DOI: 10.1016/j.euros.2021.01.005.Peer-Reviewed Original ResearchRadical nephrectomyRadical prostatectomyRadical cystectomyPartial nephrectomyHigher American Society of Anesthesiologists (ASA) scoreCounseling patientsGenitourinary (GU) cancersAmerican Society of Anesthesiologists (ASA) scoreAssociated with longer hospital LOSRisk of progressionHigher ASA scoreHospital length of stayUrologic cancer surgeryMinimally invasive approachLonger hospital LOSCase statusLength of stayASA scoreInvasive approachMulticentre analysisCancer operationsUrological cancersCancer surgeryHospital lengthKidney cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply